《新股表现》兆科眼科(06622.HK)暗盘低开0.7%报16.68元
根据辉立交易平台显示,明天挂牌的兆科眼科(06622.HK)暗盘低开0.7%报16.68元获承接,暂时最高见17.2元,现造17.1元,较上市价16.8元,高1.8%,成交48万股。
由李氏大药厂(00950.HK)分拆的兆科眼科是一间眼科制药公司,致力於疗法的研究、开发及商业化,以满足内地巨大医疗需求缺口。公司的目标是成为中国及邻近东盟市场领导者。是次上市共发售近1.24亿股,引入包括CaaS Capital、GIC、奥博资本、Golden Valley、Jennison、Mass Ave、VMS及Matthews八名基石投资者,合共认购2,546.1万股;10%公开发售获55倍超购,启动回拨机制後占比增至40%,认购一手中签率25%;股份以招股范围(15.38-16.8元)上限定价,料集资净额约19.42亿元,主要用於集团的核心产品临床开发和商业化、为其他在研候选药物持续研发活动与商业化提供资金、用作位於南沙的先进生产设施进行生产线扩张等。上市联席保荐人分别为高盛及Jefferies。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.